Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2006

View Archived Issues

Clinical update on AMG-714 for RA

2-Methoxyestradiol reduces angiogenesis and signs of arthritis in animal model

Study shows potential of methotrexate/CF-101 combination in rheumatoid arthritis

Amorcyte signs development and manufacturing agreement for AMR-001

BioProgress to acquire Segix Farma

King and Depomed to copromote Glumetza

Advisory Committee review date set for Factive sNDA in acute bacterial sinusitis

Pivotal PanVac-VF study in advanced pancreatic cancer fails to meet endpoint

APEX-AMI trial of pexelizumab fails to meet primary endpoint

Prezista launched in U.S. for treatment of antiretroviral-treatment experienced patients

Japanese filing for Nexavar for renal cell carcinoma

NDA submission for AzaSite in bacterial conjunctivitis

New phase IIb study of seliciclib in previously treated NSCLC

Fast track designation for TG-100-115 for treatment of STEMI

Revised U.S. prescribing information for Ketek

Approvable letter for Fentora in breakthrough cancer pain

CK-1827452 demonstrates dose-dependent increases in indices of cardiac function

Zerenex shows utility as treatment for hyperphosphatemia in hemodialysis patients

European submission for Atriance in T-ALL and T-LBL

FDA approval for Lucentis

Astellas discontinues development of immunosuppressant FK-778

Novel mutation pattern for the protease inhibitor PL-100 identified

Novel HIV fusion inhibitors active against enfuvirtide-resistant viruses

Monoclonal antibody against the GM-CSF receptor alpha chain shows preclinical biological activity

Novel agents imparted for the treatment of arthritis and other inflammatory conditions

New treatment strategies for cancer covered in recent patents

Antipsychotic, antidepressant agents disclosed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...